B O O K - American College of Rheumatology

thursday
10:00 AM
Optimal use of Bisphosphonates in Clinical Disorders
Felicia Cosman, MD; Helen Hayes Hospital; West Haverstraw, NY
Session Overview:
The mechanism of action of bisphosphonates has been
elucidated and has led to new insights and potential applications
for treatment of skeletal disorders. Optimizing their clinical use
and avoidance of potential complications is critically important
in the treatment of patients with skeletal disorders.
Upon completion of this session, participants should be able to:
• describe the mechanism of action of bisphosphonates
• discuss the optimal therapeutic use in treating skeletal
disorders
• describe potential novel bisphosphonates and their clinical
application
Thomas J. Murphy Ballroom
Immunopathogenesis of Systemic Sclerosis R
Moderator: Robert A. Lafyatis, MD; Boston University School of
Medicine; Arlington, MA
9:00 AM
Gene Expression Analyses - Insights into Immune Dysreguation
in Systemic Sclerosis
Filemon K. Tan, MD, PhD; University of Texas - Houston Medical
School; Houston, TX
9:30 AM
Connecting Inflammation and Fibrosis - Innate Immunity in
Systemic Sclerosis
Robert A. Lafyatis, MD; Boston University School of Medicine;
Arlington, MA
10:00 AM
The Basic Biology of IL-33 and Its Potential Role in
Inflammation and Fibrosis
Foo Y. Liew, BSc, PhD, DSc; University of Glasgow, Glasgow
Biomedical Research Centre; Glasgow, Scotland, United Kingdom
Session Overview:
Our understanding of immunity and autoimmunity in systemic
sclerosis pathogenesis has made rapid progress in both
innate adaptive immune mechanisms contributing to fibrosis.
Immune regulatory gene associations with scleroderma have
re-emphasized the importance of immune pathogenesis in this
disease.
Upon completion of this session, participants should be able to:
• describe basic immune pathogenesis in systemic sclerosis
• identify how innate immunity might lead to inflammation and
fibrosis in target organs
• interpret key profibrotic cytokines, their sources and their
roles in fibrosis
• discuss key alterations in gene regulation seen in patients with
systemic sclerosis
ACR Clinical Symposia
9:00 - 10:30 AM
B406
Pediatric Spondylarthropathies: From Genetics to the
Clinic P
Moderators: Larry B. Vogler, MD; Emory University School of
Medicine; Atlanta, GA
Carlos D. Rose, MD; duPont Hospital for Children; Wilmington,
DE
9:00 AM
Advances in the Genetics and Pathogenesis of the
Spondylarthropathies
Robert A. Colbert, MD, PhD; NIAMS/NIH; Bethesda, MD
9:30 AM
Enthesitis Related Arthritis in the Context of Juvenile Idiopathic
Arthritis: Clinical Features
Shirley Tse, MD; Hospital for Sick Children; Toronto, ON, Canada
10:00 AM
Using and Interpreting Imaging in the Diagnosis and Monitoring
of the Spondylarthropathies
Thomas J. Learch, MD; Cedar-Sinai Medical Center; Los Angeles,
CA
Session Overview:
There have been new developments in disease mechanism for
the spondylarthropathies resulting mainly form work on the
transgenic rat model and the processing of the B27 molecule.
The availability of new imaging techniques has certainly shed
light on the nature of enthesitis and the new discoveries on
the contribution of bone in the pathologic process. Finally, the
pediatric spondylarthropathies have been reclassified and now
constitute a new category of juvenile idiopathic arthritis; a
critical review of the new classification is worthy of re-visiting.
Upon completion of this session, participants should be able to:
• discuss the most widely accepted possible mechanisms of
disease associated with HLA-B27 moiety
• discuss the clinical features of enthesitis related arthritis and
the most characteristic radiologic findings that distinguishes
this group from the other forms of chronic arthritis
• discuss the pros and cons of classifying the
spondylarthropathies with the rest of the subsets of juvenile
idiopathic arthritis
Hall A3
Remission in Rheumatoid Arthritis c/r PS
Moderators: David T. Felson, MD, MPH; Boston University School
of Medicine; Boston, MA
Maarten Boers, MD, PhD, MSc; VU University Medical Center;
Amsterdam, The Netherlands
9:00 AM
Why Do We Need a New Definition of Remission in
Rheumatoid Arthritis?
Maarten Boers, MD, PhD, MSc; VU University Medical Center;
Amsterdam, The Netherlands
136
2010 Program Book